AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
She sold her startup to Salesforce. Then she had four kids and started another one.
2
Meta loses its $1.5 billion AI recruit less than a year after hiring him
3
What made Anthropic walk away from the $6 billion Decart deal?
4
“We proved there are no sacred cows in technology”: Island founder says the company can be worth tens of billions
5
Secretive defense startup Covenant emerges from stealth with $250 million at over $1 billion valuation
More news

Richard Francis

7 stories about Richard Francis
ריצרד פרנסיס נשיא ו מנכל טבע

Teva’s $40 billion comeback brings Wall Street’s biggest prize into view

30.07.26|Sophie Shulman
After years as a struggling generic-drug giant, Teva’s transformation under Richard Francis has pushed its valuation above $40 billion and raised the possibility of joining the S&P 500.
בניין חברת טבע כפר סבא

The deal that signals Teva is back

30.04.26|Sophie Shulman
A calculated biotech acquisition and strong earnings revive confidence in the pharma giant.
ריצ'רד פרנסיס מפגש העיתונאים

Teva CEO cashes in $30 million in shares in two weeks

08.03.26|Sophie Shulman
Richard Francis sells stock after Teva’s 110% rally over the past year.
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory